Teriparatide transdermal - Zosano Pharma

Drug Profile

Teriparatide transdermal - Zosano Pharma

Alternative Names: B104; B106; Teribone™ transdermal; TH 0229; ThPTH; ThPTH (1-34); ZP-PTH

Latest Information Update: 30 Aug 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator ALZA Corporation
  • Developer Asahi Kasei; Zosano Pharma
  • Class Osteoporosis therapies; Peptide hormones; Skin disorder therapies
  • Mechanism of Action Osteogenesis stimulants; Parathyroid hormone receptor type 1 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Postmenopausal osteoporosis

Highest Development Phases

  • Suspended Postmenopausal osteoporosis

Most Recent Events

  • 29 Mar 2016 Teriparatide transdermal - Zosano Pharma is available for licensing in World as of 29 Mar 2016. www.zosanopharma.com/
  • 29 Mar 2016 Suspended - Phase-I for Postmenopausal osteoporosis in Australia (Transdermal)
  • 28 Sep 2015 Eli Lilly terminates its licence for teriparatide transdermal Worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top